Under the terms of the agreement, M’s Science will grant Eisai the following rights in exchange for a certain payment: the first review right for evaluating the results of the two Phase II studies of the compound currently ongoing in Europe for depression and post-stroke therapy and the first negotiation right regarding the development and marketing of the compound.
SA4503 is a novel, small molecule, selective sigma receptor agonist with activity in preclinical models of CNS diseases to enhance neuroregeneration or maturation. Currently, two Phase II studies are being conducted in Europe for the treatment of central nervous system disorders (major depression and post-stroke recovery).
Akihiko Shimauchi, president and COO of M’s Science, said: “I am confident that this agreement facilitates the development of our novel SA4503, and enables us to offer a new treatment for depression and for post-stroke therapy.”